Arbutus Biopharma (ABUS) Change in Receivables (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Change in Receivables for 14 consecutive years, with $178.7 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Receivables rose 14667.32% year-over-year to $178.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.6 million (up 18761.76% YoY) and the FY2025 annual result came in at -$1.4 million, down 317.22% from the prior year.
• Change in Receivables rose to $178.7 million in Q1 2026 per ABUS's latest filing, from $129000.0 in the prior quarter.
• Over the last five years, Change in Receivables for ABUS reached as high as $178.7 million in Q1 2026 and fell as low as -$1.2 million in Q1 2025.
• A 5-year average of $10.5 million and a median of -$120000.0 in 2025 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2024 — Change in Receivables plunged 644.0% — and 2026, when it surged 14667.32%.
• Year by year, Change in Receivables stood at -$483000.0 in 2022, then increased by 18.22% to -$395000.0 in 2023, then jumped by 302.78% to $801000.0 in 2024, then sank by 83.9% to $129000.0 in 2025, then soared by 138458.91% to $178.7 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $178.7 million, $129000.0, and -$120000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.